Dr. Rai on Handicaps of Chemotherapy in CLL

Kanti R. Rai, MD
Published: Wednesday, Mar 22, 2017



Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the downfalls of chemotherapy in chronic lymphocytic leukemia (CLL).

Traditionally, chemotherapy has been the standard of care for CLL. Newer developments, though, have been targeted treatments. More enzymatic points have been identified, which are unique to the leukemic cell, says Rai.

The inability to preserve normal bone marrow cells is the main handicap of chemotherapy, says Rai. The hope in developing a treatment to target those points is to preserve a patient’s normal bone marrow cells.
 


Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses the downfalls of chemotherapy in chronic lymphocytic leukemia (CLL).

Traditionally, chemotherapy has been the standard of care for CLL. Newer developments, though, have been targeted treatments. More enzymatic points have been identified, which are unique to the leukemic cell, says Rai.

The inability to preserve normal bone marrow cells is the main handicap of chemotherapy, says Rai. The hope in developing a treatment to target those points is to preserve a patient’s normal bone marrow cells.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x